Xvivo Perfusion (Q1 Review): A strong start to an eventful year - Redeye
The report supported our take on increasing thoracic sales and showed continued FCF improvements (Q4 was the first quarter of positive cash flow). Still, the lower-than-expected gross margins held back a beat on profitability.
ANNONS
The report supported our take on increasing thoracic sales and showed continued FCF improvements (Q4 was the first quarter of positive cash flow). Still, the lower-than-expected gross margins held back a beat on profitability.